替莫唑胺联合贝伐单抗对星形细胞瘤的疗效及安全性  

Clinical Efficacy and Safety of Temozolomide plus Bevacizumab for Astrocytoma

作　　者：董亭方[1] 贵永堃[1] 牛晓露[1] 刘丽[1] 闫海清[1] 张平[1] 

机构地区：[1]新乡医学院第一附属医院,453000

出　　处：《实用癌症杂志》2016年第4期555-557,共3页The Practical Journal of Cancer

基　　金：河南省卫生厅科技攻关项目(编号:2011020094)

摘　　要：目的探究替莫唑胺联合贝伐单抗对星形细胞瘤的疗效和安全性。方法将研究对象分为治疗组和对照组,分别给予替莫唑胺联合贝伐单抗治疗和替莫唑胺单独治疗,治疗组15例,对照组15例。观察两组的临床效果和不良反应。结果治疗组中位疾病无进展生存期(progression free survival,PFS)为12.3个月,明显高于对照组(6.5个月),差异具有显著性意义(P<0.05);中位总生存时间(overall survival,OS)为18.1个月,与对照组的17.5个月比较无显著性差异(P>0.05)。此外,治疗组客观治疗有效率为80.00%,显著高于对照组(66.67%),差异具有显著性意义(P<0.05)。两组不良反应的发生情况相互比较,差异无统计学意义(P>0.05)。结论替莫唑胺联合贝伐单抗治疗星形细胞瘤效果明显好于替莫唑胺单独治疗,值得临床应用。Objective To explore the efficacy and safety of temozolomide plus bevacizumab for astrocytoma. Methods The patients were divided into the treatment group （treated with temozolomide combined with bevacizumab） and the control group （treated with temozolomide）, each with 15 cases. Clinical efficacy and adverse reactions of the 2 groups were observed. Results The progression-free survival in the treatment group was 12.3 months, which was significantly longer than that of the control group ,6.5 months （P 〈 0.05 ）, the overall survival in the treatment group was 18.1 months, and than the control group was 17.5 months （ P 〉 0.05 ）. Besides, the objective response rate in the treatment group was 80%, which was significantly higher than that of the control group ,66.6% , （P 〈0. 05 ）. There was no statistical difference in the side effects between the 2 group. Conclusion Temozolomide combined with bevacizumab for astrocytoma is superior to temozolomide only, and it is worthy of clinical application.

关 键 词：星形细胞瘤 替莫唑胺 贝伐单抗 

分 类 号：R730.264[医药卫生—肿瘤]